Anish Chakka
Research Subjects
Research Interests
Anish Chakka has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Arjun Pennathur
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
1 shared publication - Ashwin Somasundaram
Division of Hematology/Oncology, Department of Medicine, and
1 shared publication - Autumn Gaither-Davis
Division of Hematology/Oncology, Department of Medicine, and
1 shared publication - Curtis Tatsuoka
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
1 shared publication - Ethan Miller
Division of Hematology/Oncology, Department of Medicine, and
1 shared publication - Jingxiao Jin
Division of Hematology/Oncology, Department of Medicine, and
1 shared publication
Latest Publications
- Open Access
- 18 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
Non–small cell lung cancer exhibits the highest rates of brain metastases (BMs) among all solid tumors, presenting a major clinical challenge. The development of novel therapeutic strategies targeting BMs is clearly needed. We identified a significant enrichment of MET amplification in lung adenocarcinoma (LUAD) BMs compared with primary LUAD and extracranial metastases in oncogene driver–negative patients. Of note, MET -amplified BMs were responsive to MET inhibitors in vivo, including models with acquired MET amplification at the time of metastasis. MET alterations (amplifications and/or mutations) were also more frequently detected in circulating tumor DNA from patients with LUAD BMs than in those without BMs. MET- altered BMs also demonstrated unique genomic features compared with non– MET- altered BMs. Transcriptomic analyses revealed that in contrast to MET WT BMs, MET -amplified BMs exhibited a more inflamed tumor microenvironment and displayed evidence of metabolic adaptation, particularly a reliance on glycolysis in contrast to OXPHOS in MET WT BMs. Furthermore, MET -amplified BMs demonstrated evidence of epithelial-mesenchymal transition signaling, including increased expression of TWIST1. Patients with MET -amplified BMs had significantly shorter overall survival. These findings highlight MET amplification as a critical driver of LUAD BMs, emphasizing its potential as a therapeutic target.
- 18 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
Open AccessMET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
Non–small cell lung cancer exhibits the highest rates of brain metastases (BMs) among all solid tumors, presenting a major clinical challenge. The development of novel therapeutic strategies targeting BMs is clearly needed. We identified a significant enrichment of MET amplification in lung adenocarcinoma (LUAD) BMs compared with primary LUAD and extracranial metastases in oncogene driver–negative patients. Of note, MET -amplified BMs were responsive to MET inhibitors in vivo, including models with acquired MET amplification at the time of metastasis. MET alterations (amplifications and/or mutations) were also more frequently detected in circulating tumor DNA from patients with LUAD BMs than in those without BMs. MET- altered BMs also demonstrated unique genomic features compared with non– MET- altered BMs. Transcriptomic analyses revealed that in contrast to MET WT BMs, MET -amplified BMs exhibited a more inflamed tumor microenvironment and displayed evidence of metabolic adaptation, particularly a reliance on glycolysis in contrast to OXPHOS in MET WT BMs. Furthermore, MET -amplified BMs demonstrated evidence of epithelial-mesenchymal transition signaling, including increased expression of TWIST1. Patients with MET -amplified BMs had significantly shorter overall survival. These findings highlight MET amplification as a critical driver of LUAD BMs, emphasizing its potential as a therapeutic target.